Clinical Trial Update: A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for CM336 in relapsed or refractory autoimmune cytopenia, including immune thrombocytopenia, autoimmune hemolytic anemia, and Evans syndro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Cytopenia
• Autoimmune Hemolytic Anemia
• Evans Syndrome
• Immune Thrombocytopenia

Drugs mentioned

• CM336 (CM336)

Snippet

Sponsor: Keymed Biosciences Co.Ltd | Conditions: Autoimmune Cytopenia, Immune Thrombocytopenia (ITP) | Phase 1, Phase 2 | Status: RECRUITING